Array BioPharma reported top-line results from the ongoing phase III clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, demonstrating that the study met its primary endpoint of improving progression-free survival when compared with dacarbazine treatment.
Richard M. Simon, NCI biostatistician who likely set a record for the number of first-authored papers, and whose interests included country music, horseback riding and ballroom dancing, died May 9, at age 80. Simon joined NCI in 1974.
